Sign in

You're signed outSign in or to get full access.

PTC THERAPEUTICS (PTCT)

--

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for PTC THERAPEUTICS.

Q3 2025

→

Q2 2025

→

Q1 2025

→

Q4 2024

→

Executives

Executive leadership at PTC THERAPEUTICS.

Matthew B. Klein

Matthew B. Klein

Detailed

Chief Executive Officer

CEO
CU

Christine Utter

Detailed

Senior Vice President, Chief Accounting Officer and Head of People Services

EP

Eric Pauwels

Detailed

Chief Business Officer

LG

Lee Golden

Detailed

Executive Vice President and Chief Medical Officer

ME

Mark E. Boulding

Detailed

Executive Vice President and Chief Legal Officer

NA

Neil Almstead

Detailed

Chief Technical Operations Officer

PG

Pierre Gravier

Detailed

Chief Financial Officer

Board Members

Board of directors at PTC THERAPEUTICS.

AY

Alethia Young

Detailed

Director

AJ

Allan Jacobson

Detailed

Director

DP

David P. Southwell

Detailed

Director

ER

Emma Reeve

Detailed

Director

GD

Glenn D. Steele Jr.

Detailed

Director

JB

Jerome B. Zeldis

Detailed

Director

MS

Mary Smith

Detailed

Director

MS

Michael Schmertzler

Detailed

Chair of the Board

SS

Stephanie S. Okey

Detailed

Director

Analyst Coverage

Research analysts who have asked questions during PTC THERAPEUTICS earnings calls.

Kristen Kluska

Kristen Kluska

Cantor Fitzgerald

5 questions for PTCT

Also covers: ABEO, ADMA, AQST +24 more
PC

Paul Choi

Goldman Sachs

5 questions for PTCT

Also covers: AMRN, ARVN, ASND +13 more
TA

Tazeen Ahmad

Bank of America

5 questions for PTCT

Also covers: ACAD, ALNY, APLS +22 more
Brian Abrahams

Brian Abrahams

RBC Capital Markets

4 questions for PTCT

Also covers: ACAD, ATAI, BCRX +19 more
JS

Joseph Schwartz

Oppenheimer

4 questions for PTCT

Also covers: ASND, AUPH, BMRN +14 more
Judah Frommer

Judah Frommer

Morgan Stanley

4 questions for PTCT

Also covers: APLS, ARQT, ATAI +5 more
BC

Brian Cheng

JPMorgan Chase & Co.

3 questions for PTCT

Also covers: ALLO, BEAM, CHRS +11 more
EM

Eliana Merle

UBS

3 questions for PTCT

Also covers: ALNY, APLS, ARVN +17 more
EM

Ellie Merle

UBS Group AG

3 questions for PTCT

Also covers: ALNY, ALT, ARVN +12 more
Eric Joseph

Eric Joseph

JPMorgan Chase & Co.

3 questions for PTCT

Also covers: BEAM, BLUE, ENTA +9 more
Gena Wang

Gena Wang

Barclays

3 questions for PTCT

Also covers: ALNY, BCRX, BLUE +13 more
JB

Joel Beatty

Baird

3 questions for PTCT

Also covers: ACAD, ALKS, AMLX +11 more
JP

John Peyton Bohnsack

TD Cowen

3 questions for PTCT

Joseph Thome

Joseph Thome

TD Cowen

3 questions for PTCT

Also covers: ALKS, AMLX, ARDX +12 more
Kelly Shi

Kelly Shi

Jefferies

3 questions for PTCT

Also covers: ADCT, AGEN, ALDX +17 more
SC

Sami Corwin

William Blair

3 questions for PTCT

Also covers: ALLO, BEAM, KRYS +5 more
Ben Burnett

Ben Burnett

Stifel

2 questions for PTCT

Also covers: ALKS, ALLO, FATE +2 more
Jarwei Fang

Jarwei Fang

Citi

2 questions for PTCT

Also covers: AMLX
JH

Joe Heidt

RBC Capital Markets

2 questions for PTCT

JL

Joon Lee

Truist Securities

2 questions for PTCT

Also covers: ADVM, ALKS, AXSM +15 more
J

Judy

Leerink Partners

2 questions for PTCT

LH

Luke Herrmann

Baird

2 questions for PTCT

Also covers: ALKS, CPRX, CRNX
SC

Samantha Corwin

William Blair

2 questions for PTCT

Also covers: ALLO, BEAM, KRYS +3 more
AK

Akash Kashi

Jefferies

1 question for PTCT

DB

Danielle Brill Bongero

Raymond James

1 question for PTCT

DL

David Lebowitz

Citigroup Inc.

1 question for PTCT

Also covers: ALNY, ARWR, ASND +11 more
DS

Dingding Shi

Jefferies

1 question for PTCT

Also covers: ADCT, ASND, AUTL +6 more
Geoff Meacham

Geoff Meacham

Citigroup Inc.

1 question for PTCT

Also covers: ABBV, AMGN, BMY +11 more
Geoffrey Meacham

Geoffrey Meacham

Citi

1 question for PTCT

Also covers: ABBV, BIIB, BMY +6 more
HW

Huidong Wang

Barclays

1 question for PTCT

Also covers: ALNY, BCRX, BEAM +15 more
Khalil Fenina

Khalil Fenina

Goldman Sachs

1 question for PTCT

Also covers: FGEN, SLNO
Michael Riad

Michael Riad

Morgan Stanley

1 question for PTCT

Also covers: ACAD, ALEC, ITCI +3 more
PK

Professor Kashi

Jefferies

1 question for PTCT

RM

Richard Miller

Cantor Fitzgerald

1 question for PTCT

Also covers: ADMA, QURE
TF

Tiago Fauth

Wells Fargo

1 question for PTCT

Also covers: LQDA, VRNA, WVE

Latest news

Recent press releases and 8-K filings for PTCT.

PTC Therapeutics Reports Strong Q4 and Full-Year 2025 Results, Exceeds Revenue Guidance, and Provides Positive 2026 Outlook
PTCT
Earnings
Guidance Update
Product Launch
  • PTC Therapeutics reported full-year 2025 total net product and royalty revenue of $831 million, surpassing its guidance, with Q4 2025 revenue reaching $263 million.
  • The company ended 2025 with a strong cash position of $1.95 billion, bolstered by the $240 million monetization of its remaining Evrysdi royalty.
  • The global launch of Sephience for PKU demonstrated a strong start, contributing $111 million in revenue since its 2025 launch and $92 million in Q4 2025.
  • For 2026, the company projects product revenue of $700 million-$800 million, representing 19%-36% year-over-year growth, and anticipates reaching cash flow break-even based on expense guidance of $680 million-$720 million.
  • In its R&D pipeline, PTC Therapeutics aligned with the FDA on the Phase 3 study design for votoplam in Huntington's disease, with Novartis initiating the trial in H1 2026, and plans to discuss a single-arm study protocol for vatiquinone with the FDA in Q2 2026.
Feb 19, 2026, 9:30 PM
Transcript
PTC Therapeutics Announces Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance
PTCT
Earnings
Guidance Update
Product Launch
  • PTC Therapeutics reported full-year 2025 total net product and royalty revenue of $831 million, exceeding its guidance, and Q4 2025 revenue of $263 million. Non-GAAP R&D and SG&A OpEx for 2025 was $728 million, below guidance.
  • The company ended 2025 with $1.95 billion in cash, significantly bolstered by the $240 million monetization of the Evrysdi royalty in December 2025.
  • Sephience, a new PKU treatment, generated $92 million in Q4 2025 revenue and $111 million for the full year since its launch, with plans for commercial expansion into 20-30 countries by the end of 2026.
  • For 2026, PTC Therapeutics issued product revenue guidance of $700 million-$800 million (excluding Evrysdi royalties) and non-GAAP R&D and SG&A OpEx guidance of $680 million-$720 million, aiming for cash flow break-even.
  • In R&D, the Phase III INVEST-HD trial for Votoplam in Huntington's disease is set to begin in the first half of 2026, and discussions with the FDA regarding a new study design for Vatiquinone are scheduled for Q2 2026.
Feb 19, 2026, 9:30 PM
Transcript
PTC Therapeutics Reports Strong 2025 Results, Exceeding Revenue Guidance, and Provides 2026 Outlook
PTCT
Earnings
Guidance Update
Product Launch
  • PTC Therapeutics reported full-year 2025 total net product and royalty revenue of $831 million, exceeding its guidance, and Q4 2025 revenue of $263 million.
  • The company ended 2025 with a strong cash position of $1.95 billion following the sale of its remaining Evrysdi royalty for $240 million.
  • The new PKU product, Sephience, had a strong launch in 2025, generating $111 million in full-year revenue and $92 million in Q4, with 946 patients on commercial therapy worldwide by year-end.
  • For 2026, the company projects product revenue of $700 million-$800 million and non-GAAP R&D and SG&A expenses of $680 million-$720 million, with the potential to reach cash flow break-even.
Feb 19, 2026, 9:30 PM
Transcript
PTC Therapeutics Reports Strong Full Year 2025 Financial Results and Provides 2026 Guidance
PTCT
Earnings
Guidance Update
Product Launch
  • PTC Therapeutics reported full-year 2025 net income of $682.6 million and total revenues of $1,730.7 million, significantly up from a net loss of $363.3 million and total revenues of $806.8 million in 2024, driven by a $998.4 million collaboration and license revenue from the Novartis votoplam agreement.
  • The company ended 2025 with a strong cash position of $1.95 billion as of December 31, 2025.
  • The global launch of Sephience™ (sepiapterin) showed strong uptake, generating $92 million in revenue for Q4 2025 and a total of $111 million in 2025 since its launch.
  • PTC Therapeutics provided full-year 2026 financial guidance, projecting total product revenue between $700 million and $800 million and GAAP R&D and SG&A expenses between $775 million and $815 million.
  • Key corporate updates include alignment with the FDA on the design of the global Phase 3 INVEST-HD trial for votoplam, planned for 1H 2026, and the sale of the remaining Evrysdi® royalty for $240 million upfront in December 2025.
Feb 19, 2026, 9:14 PM
8-K
PTC Therapeutics Reports Q4 and Full Year 2025 Financial Results
PTCT
Earnings
Guidance Update
Product Launch
  • PTC Therapeutics reported full-year 2025 total revenues of $1,730.7 million and a net income of $682.6 million, a significant improvement from a net loss in the prior year.
  • The company concluded 2025 with a robust cash position of $1.95 billion as of December 31, 2025.
  • The global launch of Sephience demonstrated strong uptake, contributing $111 million in total net revenue for 2025.
  • For full-year 2026, the company projects total product revenue of $700 to $800 million.
Feb 19, 2026, 9:01 PM
Press Release
PTC Therapeutics Withdraws Translarna US Filing
PTCT
Guidance Update
Profit Warning
  • PTC Therapeutics withdrew its New Drug Application resubmission for Translarna (ataluren) for nonsense-mutation Duchenne muscular dystrophy after the FDA indicated the submitted data were unlikely to meet the agency’s threshold for substantial evidence of effectiveness.
  • This withdrawal follows a roughly two-decade effort to win U.S. approval, earlier FDA refusals, and a recent European Commission decision not to renew Translarna’s authorization.
  • PTC shares fell approximately 5.2% in after-hours trading to $67.05, down from a $70.70 close on the announcement day.
  • The CEO expressed disappointment, citing irreconcilable differences in data interpretation with the FDA, and stated the company would soon decide on the impact to patient supply.
  • Analyst commentary is mixed, with a recent published rating of Hold with a $75 price target, while TipRanks’ AI Analyst rated PTCT as an “Outperform”.
Feb 13, 2026, 12:31 AM
Morningstar
PTC Therapeutics Withdraws Translarna NDA Resubmission
PTCT
Regulatory Update
  • PTC Therapeutics, Inc. announced the withdrawal of its New Drug Application (NDA) resubmission for Translarna™ (ataluren) on February 12, 2026.
  • This decision followed U.S. Food and Drug Administration (FDA) feedback indicating that the submitted data were unlikely to meet the Agency’s threshold of substantial evidence of effectiveness to support approval.
  • Translarna was intended for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD).
Feb 12, 2026, 10:10 PM
8-K
PTC Therapeutics Withdraws Translarna NDA Resubmission
PTCT
Product Launch
  • PTC Therapeutics withdrew the New Drug Application (NDA) resubmission for Translarna™ (ataluren), a treatment for nonsense mutation Duchenne muscular dystrophy (DMD).
  • This decision followed U.S. Food and Drug Administration (FDA) feedback indicating the data were unlikely to meet the Agency's effectiveness threshold for approval.
  • CEO Matthew B. Klein, M.D., stated the company is disappointed that FDA approval cannot be achieved for Translarna in the U.S..
Feb 12, 2026, 10:00 PM
Press Release
PTC Therapeutics Announces Preliminary 2025 Financial Results and 2026 Guidance
PTCT
Earnings
Guidance Update
Product Launch
  • PTC Therapeutics reported unaudited 2025 total product and royalty revenue of approximately $823.4 million, with unaudited Sephience Q4 2025 net revenue at approximately $92.5 million and total 2025 Sephience net revenue of approximately $112.1 million since launch.
  • The company provided 2026 product revenue guidance of $700 million to $800 million, which represents 19-36% year-over-year growth.
  • Cash, cash equivalents, and marketable securities totaled approximately $1.94 billion as of December 31, 2025.
  • PTC Therapeutics plans to initiate a Phase 3 trial for its votoplam Huntington's disease program in the first half of 2026, with the FDA indicating openness to a potential Accelerated Approval pathway.
Jan 12, 2026, 5:00 PM
8-K
PTCT Reports Strong 2025 Performance and Provides 2026 Guidance
PTCT
Guidance Update
Product Launch
New Projects/Investments
  • PTCT exceeded its 2025 revenue guidance, achieving $823 million in total revenue and ending the year with over $1.94 billion in cash.
  • The Safiyance launch demonstrated strong momentum, generating $112 million in total revenue since launch, with $92.5 million in Q4 2025 net revenue, and 946 patients on commercial therapy worldwide as of December 31st.
  • For 2026, PTCT provided revenue guidance of $700-$800 million and OpEx guidance of $680-$720 million, positioning the company for potential cash flow breakeven.
  • The company advanced its pipeline, including the Vodaplam Huntington's Disease Program with a planned Phase 3 study, and sold the remaining Evrysdi royalty for $240 million in milestones in December 2025.
Jan 12, 2026, 5:00 PM
Transcript

Earnings Transcripts

Quarterly earnings call transcripts for PTC THERAPEUTICS.

Q4 2025

Feb 19, 2026

→

Q3 2025

Nov 4, 2025

→

Q2 2025

Aug 7, 2025

→
View All Transcripts
Fintool

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Matthew B. Klein say about margins?What are PTC THERAPEUTICS's strategic priorities?How is PTC THERAPEUTICS positioned vs competitors?How did PTC THERAPEUTICS do last quarter?